☆ 4.8 Review

Deciphering breast cancer: from biology to the clinic

CELL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biotechnology & Applied Microbiology

Targeting HER2-positive breast cancer: advances and future directions

Sandra M. Swain et al.

Summary: The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2(+) breast cancer. Here, Swain et al. review the current standard of care for HER2(+) breast cancer, describe mechanisms of drug resistance, and focus on next-generation platforms and therapies for the treatment of this disease.

NATURE REVIEWS DRUG DISCOVERY (2023)

添加到收藏夹

Article Oncology

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials

Aranzazu Fernandez-Martinez et al.

Summary: Assessment of tumor-infiltrating lymphocytes (TILs) and immune-related gene expression signatures can predict better treatment outcomes in patients with early-stage ERBB2/HER2-positive breast cancer. However, the combined prognostic value of these immune activation measures is not known.

JAMA ONCOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Multi-omic machine learning predictor of breast cancer therapy response

Stephen-John Sammut et al.

Summary: This study demonstrates that the response to breast cancer treatment is influenced by the pre-treatment tumour ecosystem, and a machine learning model incorporating multi-omic features can predict pathological complete response.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Oncology

Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer

Nicholas P. McAndrew et al.

Summary: The natural history of hormone receptor-positive breast cancer is more favorable than other subtypes. Traditional endocrine therapy and molecularly targeted agents have improved outcomes. Treatment plans should take multiple factors into account.

JCO ONCOLOGY PRACTICE (2022)

添加到收藏夹

Article Oncology

Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment

Takashi Semba et al.

Summary: The study identified that high phosphorylated JNK level in TNBC is associated with increased Treg infiltration. Inhibition of JNK signaling led to reduced tumor growth and Treg infiltration, and increased CD8(+) T cell infiltration, possibly through suppression of CCL2 secretion. This suggests that targeting the JNK/C-JUN/CCL2 axis may offer new therapeutic strategies for combating the aggressiveness of TNBC.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Oncology

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Fabrice Andre et al.

Summary: This article provides updated recommendations on the appropriate use of breast cancer biomarker assay results in guiding adjuvant endocrine and chemotherapy decisions for early-stage breast cancer. Based on the latest literature and expert consensus, specific biomarker assay results can be used to guide treatment decisions for patients who meet certain criteria. However, other factors such as disease stage, comorbidities, and patient preferences should also be considered.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

Breast tumor microenvironment structures are associated with genomic features and clinical outcome

Esther Danenberg et al.

Summary: Imaging mass cytometry profiling of 693 breast tumors revealed 10 recurrent tumor microenvironment spatial structures, associated with genomic profiles and outcomes. These multicellular structures within the TME, varying in vascular content, stromal activation, and leukocyte composition, could improve patient stratification and link spatial organization to local TME function.

NATURE GENETICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell et al.

Summary: This study demonstrates that the addition of Capivasertib to fulvestrant improves progression-free survival and overall survival in women with aromatase inhibitor-resistant advanced breast cancer. The expanded genetic testing panel suggests that Capivasertib predominantly benefits patients with alterations in the PI3K/AKT/PTEN pathway.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers

Christy Hong et al.

Summary: Chromosomal instability (CIN) drives cancer cell evolution, metastasis, and therapy resistance. This study reveals that the inactivation of cGAS-STING signaling selectively impairs the survival of triple-negative breast cancer cells with CIN. Furthermore, blockade of IL-6 signaling using tocilizumab selectively impairs the growth of triple-negative breast cancer cells with CIN.

NATURE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Daniel Zingg et al.

Summary: The truncation of exon 18 of Fgfr2 is identified as a potent driver mutation, while FGFR2 full-length amplifications require cooperation with other driver genes. Therefore, tumors with FGFR2 variants involving truncated E18 should be considered for FGFR-targeted therapies.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Hope S. Rugo et al.

Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) a randomised, open-label, multicentre, phase 3 trial

Francois-Clement Bidard et al.

Summary: The PADA-1 trial aimed to show the efficacy of early therapeutic targeting of rising ESR₁ mutation in blood (bESR₁(mut)), while assessing the safety of combination fulvestrant and palbociclib. Results demonstrated that early therapeutic targeting of bESR₁(mut) resulted in significant clinical benefit.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors

Elisa Rivas et al.

Summary: This study identifies a population of cancer-associated fibroblasts that are involved in suppressing the effectiveness of trastuzumab-induced ADCC in HER2+ breast cancer patients who do not respond to HER2-targeted therapy. The presence of this cellular subset, activated by TGF-beta, is related to low IL2 activity in the tumor microenvironment. Stimulation of the IL2 pathway in the tumor stroma restores the anti-cancer efficiency of trastuzumab in unresponsive tumors.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Review Oncology

Targeting CDK4 and CDK6 in cancer

Shom Goel et al.

Summary: Dysregulation of CDK4 and CDK6 promotes the growth and survival of several cancer types. CDK4/6 inhibitors have become the standard of care for advanced hormone receptor-positive breast cancer. Better understanding of their mechanisms of action and exploring new therapeutic opportunities are crucial.

NATURE REVIEWS CANCER (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Multi-omic machine learning predictor of breast cancer therapy response

Stephen-John Sammut et al.

Summary: The response to therapy in breast cancers is influenced by the pre-treated tumour ecosystem, and predictive models integrating multi-omics features through machine learning can be used to predict treatment outcomes. The degree of residual disease following therapy is monotonically associated with pre-therapy features of the tumour.

NATURE (2022)

添加到收藏夹

Article Oncology

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Yuanyuan Zhang et al.

Summary: The study indicates that high levels of baseline CXCL13(+) T cells are associated with effective responses to combination therapy in triple-negative breast cancer patients. These cells increase following combination therapy but decrease after monotherapy, highlighting their importance in predicting treatment outcomes.

CANCER CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer

Theresa E. Hickey et al.

Summary: Studies have shown that androgen receptor (AR) plays a tumor suppressor role in estrogen receptor (ER)-positive breast cancer, with AR activation helping to suppress cell cycle genes and promote the expression of tumor suppressor genes, enhancing therapeutic responses.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Population-Based Study of Genes Previously Implicated in Breast Cancer

Chunling Hu et al.

Summary: This study provides population-based estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known cancer-predisposition genes. The results highlight the varying levels of risk associated with different genes, such as high risk for BRCA1 and BRCA2 and moderate risk for PALB2, as well as associations with specific subtypes of breast cancer for genes like RAD51C and RAD51D.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Medicine, General & Internal

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky et al.

Summary: The study showed that among premenopausal women with hormone-receptor-positive, HER2-negative breast cancer and one to three positive lymph nodes with a recurrence score of 25 or lower, the addition of chemotherapy to endocrine therapy led to longer invasive disease-free survival and distant relapse-free survival compared to endocrine therapy alone. However, postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy in terms of invasive disease-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart et al.

Summary: The MINDACT trial demonstrated that patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy had excellent 5-year distant metastasis-free survival. The long-term follow-up results, including exploratory analysis by age, further support the use of genomic testing in identifying patients who can forgo chemotherapy. Chemotherapy showed different effects on distant metastasis-free survival based on age and nodal status, especially in hormone receptor-positive, HER2-negative disease.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions

Alma Andersson et al.

Summary: This study utilized Spatial Transcriptomics technology to investigate gene expression in HER2-positive breast tumors, identifying shared gene signatures for immune and tumor processes and developing a predictive model for cellular interactions.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast

Bhupinder Pal et al.

Summary: Global changes in breast heterogeneity were examined across different states through single-cell transcriptome analysis, revealing notable variations in the stroma of post-menopausal women and a discrete subset of cycling cells in tumor samples. Comparison between preneoplastic BRCA1(+/-) tissue and tumors highlighted global changes in the immune microenvironment. Proliferative CD8(+) T cells were found to characterize certain breast cancer subtypes, suggesting potential differences in immunotherapy targets.

EMBO JOURNAL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Breast tumours maintain a reservoir of subclonal diversity during expansion

Darlan C. Minussi et al.

Summary: Breast tumors and cell lines consist of numerous subclones organized into a few major superclones. Following clonal TP53 mutations, loss-of-heterozygosity events, and genome doubling, primary tumors undergo a period of transient genomic instability, with ongoing copy number evolution during expansion. Subcloned daughter cells demonstrate genomic rediversification, showing that triple-negative breast cancers continually evolve chromosome aberrations and maintain subclonal diversity during primary tumor growth.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

Ayse Bassez et al.

Summary: The study found that in breast cancer patients, anti-PD1 treatment can lead to clonal expansion of PD1-expressing T cells in a subset of tumors, regardless of tumor subtype. The expansion mainly involves CD8(+) T cells and CD4(+) T cells with distinct immune cell characteristics.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic profile of advanced breast cancer in circulating tumour DNA

Belinda Kingston et al.

Summary: Genomic profiling of advanced breast cancer using plasma circulating tumour DNA sequencing revealed diverse subclonal resistance mutations, with distinct mutational processes identified in ER-positive breast cancer. This study highlights the importance of subclonal diversification in pre-treated advanced breast cancer, presenting novel therapeutic opportunities.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Cell Biology

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors

Roman Uzhachenko et al.

Summary: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay metastatic breast cancer progression, while also enhancing the efficacy of T cell-based therapies by inducing chemokines that recruit activated CD8(+) T cells to the tumor. The metabolic stress induced by CDK4/6i treatment in breast cancer cells plays a key role in this process, suggesting a link between tumor metabolic vulnerabilities and anti-tumor immunity.

CELL REPORTS (2021)

添加到收藏夹

Article Genetics & Heredity

A single-cell and spatially resolved atlas of human breast cancers

Sunny Z. Wu et al.

Summary: This study presents a comprehensive transcriptional atlas of the cellular architecture of breast cancer, identifying recurrent neoplastic cell heterogeneity and new immune cell populations associated with clinical outcomes. A multi-omic atlas integrates single-cell RNA sequencing, spatial transcriptomics, and immunophenotyping to stratify breast cancer into nine ecotypes with unique cellular compositions and clinical outcomes.

NATURE GENETICS (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity

Zhuo Zhang et al.

Summary: The study identified tumoral ring finger protein 2 as a negative regulator of antitumor immunity in various human cancers, deletion of related genes can induce durable tumor rejection and establish immune memory.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

Jason I. Griffiths et al.

Summary: The study reveals that early-stage estrogen receptor-positive breast cancer patients receiving combination cyclin-dependent kinase inhibitors and endocrine therapy develop resistance through a shift from estrogen to alternative growth signal-mediated proliferation, with convergent clonal evolution mechanisms identified.

NATURE CANCER (2021)

添加到收藏夹

Review Physiology

STEM CELLS AND THE DIFFERENTIATION HIERARCHY IN MAMMARY GLAND DEVELOPMENT

Nai Yang Fu et al.

PHYSIOLOGICAL REVIEWS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Pan-cancer analysis of whole genomes

Peter J. Campbell et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

The single-cell pathology landscape of breast cancer

Hartland W. Jackson et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

The evolutionary history of 2,658 cancers

Moritz Gerstung et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer

Yann Kieffer et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Oncology

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Genetics & Heredity

Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases

Zheng Hu et al.

NATURE GENETICS (2020)

添加到收藏夹

Article Oncology

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Stephen R. D. Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A Emens et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortes et al.

LANCET (2020)

添加到收藏夹

Review Medicine, General & Internal

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Harold J. Burstein

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome

Gil Friedman et al.

NATURE CANCER (2020)

添加到收藏夹

Review Oncology

The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism

Gerta Hoxhaj et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Article Oncology

Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer

H. Raza Ali et al.

NATURE CANCER (2020)

添加到收藏夹

Article Oncology

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets

Luca Cassetta et al.

CANCER CELL (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

Tina Gruosso et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups

Oscar M. Rueda et al.

NATURE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer

Luigi Formisano et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Review Oncology

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

Ana C. Garrido-Castro et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer

Johanna Wagner et al.

CELL (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic characterization of metastatic breast cancers

Francois Bertucci et al.

NATURE (2019)

添加到收藏夹

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Joseph A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Genetics & Heredity

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Lindsay Angus et al.

NATURE GENETICS (2019)

添加到收藏夹

Article Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

添加到收藏夹

Article Cell Biology

An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer

Yin Wu et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Genetics & Heredity

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

Nasim Mavaddat et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2019)

添加到收藏夹

Article Oncology

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Y. Bareche et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer

Ana Costa et al.

CANCER CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

Charissa Kim et al.

CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

Elham Azizi et al.

CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing

Anna K. Casasent et al.

CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

Peter Savas et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer

Darren K. Patten et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

Pedram Razavi et al.

CANCER CELL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging

Leeat Keren et al.

CELL (2018)

添加到收藏夹

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Maki Tanioka et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Karoline B. Kuchenbaecker et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Oncology

Preventive therapy for cancer

Jack Cuzick

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou et al.

NATURE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

Jennifer L. Guerriero et al.

NATURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

Woosung Chung et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Juan M. Cejalvo et al.

CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis

Josee-Lyne Ethier et al.

BREAST CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Oncology

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Peter Savas et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

The global decrease in cancer mortality: trends and disparities

D. Hashim et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

Serena Nik-Zainal et al.

NATURE (2016)

添加到收藏夹

Article Genetics & Heredity

Punctuated copy number evolution and clonal stasis in triple-negative breast cancer

Ruli Gao et al.

NATURE GENETICS (2016)

添加到收藏夹

Article Medicine, General & Internal

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

F. Cardoso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

Bernard Pereira et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹

Article Medicine, General & Internal

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases

Katherine A. Hoadley et al.

PLOS MEDICINE (2016)

添加到收藏夹

Review Oncology

Hereditary breast and ovarian cancer: new genes in confined pathways

Finn Cilius Nielsen et al.

NATURE REVIEWS CANCER (2016)

添加到收藏夹

Review Oncology

The biology and function of fibroblasts in cancer

Raghu Kalluri

NATURE REVIEWS CANCER (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

Giovanni Ciriello et al.

CELL (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Neutrophils support lung colonization of metastasis-initiating breast cancer cells

Stefanie K. Wculek et al.

NATURE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Progesterone receptor modulates ERα action in breast cancer

Hisham Mohammed et al.

NATURE (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

Lucy R. Yates et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Oncology

ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer

Rinath Jeselsohn et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

Charlotte K. Y. Ng et al.

GENOME BIOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Dejan Juric et al.

NATURE (2015)

添加到收藏夹

Article Oncology

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

M. Piccart et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

Aleix Prat et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Clonal evolution in breast cancer revealed by single nucleus genome sequencing

Yong Wang et al.

NATURE (2014)

添加到收藏夹

Review Oncology

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight

Cathrin Brisken

NATURE REVIEWS CANCER (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Life History of 21 Breast Cancers

Serena Nik-Zainal et al.

CELL (2012)

添加到收藏夹

Article Multidisciplinary Sciences

The landscape of cancer genes and mutational processes in breast cancer

Philip J. Stephens et al.

NATURE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Sohrab P. Shah et al.

NATURE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Whole-genome analysis informs breast cancer response to aromatase inhibition

Matthew J. Ellis et al.

NATURE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Sequence analysis of mutations and translocations across breast cancer subtypes

Shantanu Banerji et al.

NATURE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt et al.

NATURE (2012)

添加到收藏夹

Article Multidisciplinary Sciences

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis et al.

NATURE (2012)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

添加到收藏夹

Article Oncology

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

Nicholas Turner et al.

CANCER RESEARCH (2010)

添加到收藏夹

Article Cell & Tissue Engineering

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

Gemma Molyneux et al.

CELL STEM CELL (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Genome remodelling in a basal-like breast cancer metastasis and xenograft

Li Ding et al.

NATURE (2010)

添加到收藏夹

Article Oncology

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Aleix Prat et al.

BREAST CANCER RESEARCH (2010)

添加到收藏夹

Article Oncology

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Joel S. Parker et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

Elgene Lim et al.

NATURE MEDICINE (2009)

添加到收藏夹

Review Oncology

Histological and molecular types of breast cancer: is there a unifying taxonomy?

Britta Weigelt et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2009)

添加到收藏夹

Letter Medicine, General & Internal

HER2 status and benefit from adjuvant trastuzumab in breast cancer

Soonmyung Paik et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Jason I. Herschkowitz et al.

GENOME BIOLOGY (2007)

添加到收藏夹

Article Oncology

Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis

R Mehra et al.

CANCER RESEARCH (2005)

添加到收藏夹

Article Medicine, General & Internal

Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors

G Danaei et al.

LANCET (2005)

添加到收藏夹

Article Oncology

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

R Rouzier et al.

CLINICAL CANCER RESEARCH (2005)

添加到收藏夹

Article Medicine, General & Internal

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

S Paik et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

Review Oncology

Towards an integrated model for breast cancer etiology - The lifelong interplay of genes, lifestyle, and hormones

SE Hankinson et al.

BREAST CANCER RESEARCH (2004)

添加到收藏夹

Article Oncology

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

DB Agus et al.

CANCER CELL (2002)

添加到收藏夹

Article Multidisciplinary Sciences

Gene expression profiling predicts clinical outcome of breast cancer

LJ van't Veer et al.

NATURE (2002)

添加到收藏夹

Article Multidisciplinary Sciences

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

T Sorlie et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

添加到收藏夹

Article Medicine, General & Internal

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

DJ Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

Review Cell Biology

Untangling the ErbB signalling network

Y Yarden et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular portraits of human breast tumours

CM Perou et al.

NATURE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.